Tulane Home Tulane Shield logo linking to site home page

Lymphoma Clinical Trials

PCYC-1141-CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab Versus Placebo in Combination With Rituximab in Treatment Naive Subjects With Follicular Lymphoma
More Information

ACE-LY-003
An Open-Label, Phase 1b/2 Study  of Acalabrutinib Alone or in Combination Therapy in Subjects with B-Cell Non-Hodgkin Lymphoma
More Information

Alliance A051301
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
More Information

S1318
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients > 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia
More Information

S1608
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
More Information

SGN35-028
A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T-Cell Lymphoma (PTCL)
More Information

ICP-CL-00107        
A Phase I, Multicenter, Open-Label, Dose Escalation Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell Malignancies.
More Information

CS1001-201
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
More Information

LYM 155
Single Arm, Phase II Study of Acalabrutinib as Post-Autologous Blood or Marrow Transplant (BMT) Maintenance Therapy in Subjects with Mantle Cell Lymphoma
More Information

SGN35-032
A Dual-Cohort, Open-Label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) with Less Than 10% CD30 Expression
More Information

LOXO-BTK-20020
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
More Information

LOXO-BTK-20019
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naive Mantle Cell Lymphoma (BRUIN MCL-321)
More Information

XPORT-DLBCL-030A
Phase 2/3, Multicenter, Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
More Information